4.51
+0.16(+3.68%)
Currency In USD
| Previous Close | 4.35 |
| Open | 4.48 |
| Day High | 4.66 |
| Day Low | 4.3 |
| 52-Week High | 28.6 |
| 52-Week Low | 4.2 |
| Volume | 235,502 |
| Average Volume | 695,940 |
| Market Cap | 3.18M |
| PE | -0.24 |
| EPS | -18.93 |
| Moving Average 50 Days | 11.8 |
| Moving Average 200 Days | 7.74 |
| Change | 0.16 |
If you invested $1000 in Artelo Biosciences, Inc. (ARTL) since IPO date, it would be worth $10.78 as of September 08, 2025 at a share price of $4.51. Whereas If you bought $1000 worth of Artelo Biosciences, Inc. (ARTL) shares 5 years ago, it would be worth $55.8 as of September 08, 2025 at a share price of $4.51.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Artelo Biosciences Announces Closing of $3.0 Million Public Offering
GlobeNewswire Inc.
Sep 05, 2025 8:05 PM GMT
SOLANA BEACH, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, derm
Artelo Biosciences Announces Pricing of $3.0 Million Public Offering
GlobeNewswire Inc.
Sep 04, 2025 12:37 PM GMT
SOLANA BEACH, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, derm
Artelo Biosciences Announces Proposed Underwritten Public Offering
GlobeNewswire Inc.
Sep 03, 2025 8:35 PM GMT
SOLANA BEACH, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, derm